Lipid nanoparticle-delivered mRNA IL-12 remodels the tumor microenvironment to potentiate neoantigen cancer vaccine efficacy
Personalized cancer vaccines (PCVs) targeting tumor-specific neoantigens have emerged as a promising strategy for cancer immunotherapy; however, their clinical efficacy remains limited by insufficient immunogenicity and inadequate remodeling of the tumor microenvironment (TME). To overcome these limitations, we investigated whether lipid nanoparticle (LNP)-based cytokine mRNA delivery could function as an immune modulator to enhance neoantigen vaccine efficacy. We evaluated the combinatorial effects of mRNA-based cytokines (GM-CSF, IL-12, and IL-15) with MHC class I- and class II-restricted neoantigen vaccines in a syngeneic MC38 colon cancer model. Following peritumoral administration, LNP-mediated mRNA delivery enabled localized cytokine expression, facilitating enhanced intratumoral immune activation while limiting systemic exposure. Among the candidates, mRNA-encoded IL-12 provided the greatest therapeutic benefit when combined with neoantigen vaccination, leading to robust tumor suppression and prolonged survival in both subcutaneous and peritoneal metastasis models. Mechanistically, IL-12 markedly enhanced MHC class II-restricted CD4⁺ T cell responses, as evidenced by increased IFN-γ and TNF-α production. Enhanced CD8⁺ T cell responses were also observed within the tumor microenvironment. These changes were accompanied by increased antigen-presenting cell activation, including dendritic cells and macrophages. Furthermore, IL-12-based combination therapy reshaped the TME by increasing tumor-infiltrating lymphocytes and effector T cells while reducing immunosuppressive regulatory T cells, thereby establishing a more immunostimulatory tumor milieu. Collectively, our findings demonstrate that LNP-mediated mRNA cytokine delivery enables effective in situ immune modulation, providing a biomaterial-based strategy to enhance neoantigen vaccine efficacy through controlled cytokine exposure and TME remodeling.
Authors
- Dahyeon Ha (ORCID: https://orcid.org/0009-0001-1859-0454)
- Subin Yoon (ORCID: https://orcid.org/0000-0002-7970-1664)
- Yu‐Sun Lee (ORCID: https://orcid.org/0000-0001-8358-984X)
- Sohee Jo
- Jung Sik Lim
- Ayoung Oh
- Huijeong Choi
- Min-Ho Kang
- Jisun Lee
- Seongje Cho
- Jungmin Kim
- Sowon Lee
- Jae-Hwan Nam
- Sang-In Park
- Yeeun Lee
- Seonghyun Lee
- Woori Kwak
Institutions
- Daegu Haany University (KR)
- The Catholic University of Korea Bucheon St. Mary's Hospital (KR)
- Korea Disease Control and Prevention Agency (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1186/s12951-026-05252-x
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00